Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Investor Presentation

Acutaas Chemicals Investor Presentation: Key Takeaways

Acutaas Chemicals delivered strong Q1 FY27 results with 59% YoY revenue growth. Management is focused on scaling high-margin Pharma Intermediates and CDMO segments while maintaining operational efficiencies.

Guidance and delivery
Management target Revenue 25.0% FY27
Highlights
Revenue growth59.1% YoY in Q1 FY27
MarginsEBITDA margins expanded to 34.3% due to product mix
Demand visibilityStrong momentum in CDMO and Pharma Intermediates
Management confidenceConfident in 25% full-year growth

Growth

Q1 FY27 Revenue rose 59.1% YoY to ₹3,297 Mn; EBITDA surged 122.1% and PAT grew 70.4% YoY.

Outlook

Management guides for 25% revenue growth for the full year with stable margins.

Risks

Muted performance in commodity chemicals segment and lower other income impacting PAT margins were noted.

Last quarter's promises, checked

Delivered

  • Guided 25% revenue growth for FY27 → delivered 59.1% in Q1 (= BEAT)
  • Guided EBITDA margin maintenance → delivered 34.3% vs 34.5% FY26 (= BEAT)
  • Guided H1 contribution ~40% of top line → Q1 revenue ₹3,297 Mn on track (= BEAT)

Partly delivered

  • Guided pilot plant completion by Q2 FY27 → construction ongoing (= PARTIAL)
  • Guided electrolyte additive phase 2 completion Q1 FY27 → spillover capex remains (= PARTIAL)

Missed

  • Guided BFC recovery to offset commodity weakness → Specialty Chemicals fell 10.6% (= MISS)
Source

Investor Presentation filed with BSE, NSE: ACUTAAS. Summary written with AI assistance from the document.

Read the document ↗

Acutaas Chemicals Ltd: key numbers

Share price
₹3,272.50
Market cap
₹26,792 Cr
Revenue (annual)
₹1,339 Cr
Net profit (annual)
₹356.3 Cr
P/E (TTM)
69.4×Sector 50.4×
Promoter holding
32.66%+0.00% QoQ
FII holding
21.61%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Acutaas Chemicals Ltd

All →
19:20 IST BSE
Management Change

Acutaas Chemicals Management Change

Acutaas Chemicals Limited has announced the re-appointment of Ram Mohan Lokhande as Executive Director and Anita Bandyopadhyay as Non-Executive Independent Director for a 60-month term.

20:03 IST BSE
Acquisition

Acutaas Chemicals Acquisition Worth ₹0.01 Cr

Acutaas Chemicals will acquire 100% of Enchem Ami Organics Private Limited for Rs. 1 Lakh, making it a wholly owned subsidiary.

Value
₹0.01 Cr
Execution
One month
19:36 IST BSE
Merger & Restructuring

Acutaas Chemicals Merger & Restructuring Worth ₹0.01 Cr

Acutaas Chemicals will acquire 100% equity stake in step-down subsidiary Enchem Ami Organics for Rs. 1 Lakh, making it a direct wholly-owned subsidiary.

Value
₹0.01 Cr
Execution
within one month
17:22 IST BSE
Annual General Meeting

Acutaas Chemicals Annual General Meeting

Acutaas Chemicals Limited conducted its 19th Annual General Meeting on September 24, 2026, where shareholders transacted various ordinary and special business items.

17:59 IST BSE
Patent

Acutaas Chemicals Patent

Acutaas Chemicals Limited has received a patent from the Indian Patent Office for a process to prepare 2,4-dimethylthiophenol. The company now holds 11 patents.

12:04 IST BSE
Capacity Expansion

Acutaas Chemicals Capacity Expansion

Acutaas Chemicals Limited inaugurated a new state-of-the-art Pilot Plant at Unit 1 in Sachin, Surat. The facility supports R&D for high potency active pharmaceutical ingredients.

pilot plant
1.0 plants